M
MacroGenics D
D
MGNX
1.51000
USD
-0.02
(-0.98%)
مغلق
حجم التداول
0
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
95,266,388
الأخبار المقالات
العنوان: MacroGenics
القطاع: Healthcare
الصناعة: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.